Ardelyx

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2007-01-01

Employees: 267

Market Cap: $1.4B

Website: http://www.ardelyx.com

Introduction: Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Clinical Trials

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

Phase 2

Recruiting

Conditions: Irritable Bowel Syndrome with Constipation (IBS-C)

Interventions: Drug: Tenapanor
Drug: Placebo

First Posted Date: 2024-08-14

Last Posted Date: 2025-01-17

Lead Sponsor: Ardelyx

Target Recruit Count: 72

Registration Number: NCT06553547

Locations: 🇺🇸
Texas Digestive Specialists, Harlingen, Texas, United States
🇺🇸
Florida Pharmaceutical Research and Associates, Inc., South Miami, Florida, United States

An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females

Phase 1

Completed

Conditions: Lactation

Interventions: Drug: Tenapanor

First Posted Date: 2024-01-12

Last Posted Date: 2024-07-11

Lead Sponsor: Ardelyx

Target Recruit Count: 7

Registration Number: NCT06203444

Locations: 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
🇺🇸
DDSI, Oklahoma City, Oklahoma, United States

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Phase 3

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)

Interventions: Drug: Tenapanor

First Posted Date: 2023-06-15

Last Posted Date: 2024-12-13

Lead Sponsor: Ardelyx

Target Recruit Count: 150

Registration Number: NCT05905926

Locations: 🇺🇸
Advantage Clinical Trials, Bronx, New York, United States
🇺🇸
Frontier Clinical Research, Kingwood, West Virginia, United States
🇺🇸
G & L Research, LLC, Foley, Alabama, United States

and more 14 locations

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Phase 3

Recruiting

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)

Interventions: Drug: Tenapanor 25 mg bid
Drug: Placebo
Drug: Tenapanor 50 MG

First Posted Date: 2022-12-08

Last Posted Date: 2024-12-17

Lead Sponsor: Ardelyx

Target Recruit Count: 180

Registration Number: NCT05643534

Locations: 🇺🇸
Proactive Clinical Research, El Paso, Texas, United States
🇺🇸
G & L Research, LLC, Foley, Alabama, United States
🇺🇸
Eclipse Clinical Research, Tucson, Arizona, United States

and more 29 locations

A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

Phase 2

Completed

Conditions: Hyperkalemia

Interventions: Drug: RDX013
Drug: Placebo

First Posted Date: 2021-03-04

Last Posted Date: 2022-05-04

Lead Sponsor: Ardelyx

Target Recruit Count: 109

Registration Number: NCT04780841

Locations: 🇺🇸
Horizon Research Group LLC, Coral Gables, Florida, United States
🇺🇸
Panax Clinical Research LLC, Miami Lakes, Florida, United States
🇺🇸
NW Louisiana Nephrology Assoc, Shreveport, Louisiana, United States

and more 3 locations

Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

Phase 4

Completed

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis
Hyperphosphatemia

Interventions: Drug: Tenapanor

First Posted Date: 2020-09-16

Last Posted Date: 2023-03-29

Lead Sponsor: Ardelyx

Target Recruit Count: 333

Registration Number: NCT04549597

Locations: 🇺🇸
South Florida Research Institute, Lauderdale Lakes, Florida, United States

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

Phase 4

Completed

Conditions: Hyperphosphatemia
End Stage Renal Disease

Interventions: Drug: Tenapanor
Drug: Sevelamer Carbonate

First Posted Date: 2019-06-18

Last Posted Date: 2023-03-29

Lead Sponsor: Ardelyx

Target Recruit Count: 172

Registration Number: NCT03988920

Locations: 🇺🇸
Ardelyx Site #509, Houston, California, United States

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

Phase 2

Completed

Conditions: Hyperphosphatemia

Interventions: Drug: Placebo
Drug: Tenapanor
Drug: Phosphate Binder Agents

First Posted Date: 2019-01-31

Last Posted Date: 2023-03-06

Lead Sponsor: Ardelyx

Target Recruit Count: 236

Registration Number: NCT03824587

Locations: 🇺🇸
Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸
Mountain Kidney & Hypertension Associates, P.A., Asheville, North Carolina, United States
🇺🇸
California Institute of Renal Research - Chula Vista, Chula Vista, California, United States

and more 45 locations